Introduction {#Sec1}
============

Ventilator-associated pneumonia (VAP) occurs in a considerable proportion of patients undergoing mechanical ventilation and is associated with substantial morbidity, two-fold mortality, and excess cost \[[@CR1]\]. Several studies have identified *Pseudomonas aeruginosa* as the most frequent microorganism in patients with VAP \[[@CR2]\]. Tracheobronchial colonization and duration of mechanical ventilation are the two most important risk factors for VAP \[[@CR3]\]. Although risk factors for VAP and tracheobronchial colonization are probably similar, outcomes of patients with VAP and those with tracheobronchial colonization are clearly different \[[@CR3], [@CR4]\].

According to the results of a recent experimental study, there is a pathogenic interaction between *Candida albicans* and *P. aeruginosa*, suggesting that *P. aeruginosa* could be more virulent in the presence of *C. albicans* \[[@CR5]\]. Other experimental studies identified physical, chemical, and environmental similarities between the two pathogens \[[@CR6], [@CR7]\]. Moreover, a recent clinical study identified *Candida* spp. tracheobronchial colonization as an independent risk factor for *P. aeruginosa* VAP \[[@CR8]\]. Therefore we conducted this retrospective case--control study to determine the impact of antifungal treatment on *P. aeruginosa* VAP or tracheobronchial colonization in patients with *Candida* spp. tracheobronchial colonization.

Patients and methods {#Sec2}
====================

This observational retrospective case--control study was conducted in a 30-bed medical and surgical intensive care unit (ICU) from January 2004 to January 2005. No informed consent was required by the Institutional Review Board because of the retrospective and noninterventional design of the study.

All patients intubated and ventilated for longer than 48 h who had tracheobronchial colonization by *Candida* spp. were eligible for this study. Patients with *P. aeruginosa* VAP or tracheobronchial colonization diagnosed before or at the same time as *Candida* spp. tracheobronchial colonization were excluded. Patients were identified using the electronic files of mycology laboratory. Data collection was based on retrospective chart review.

All patients were screened on endotracheal aspirate for *Candida* spp. and *P. aeruginosa* at ICU admission and weekly thereafter. In addition, other microbiologic examinations were performed according to patient status. Antifungal treatment and its duration were based on medical staff decisions.

Definitions {#Sec3}
-----------

Tracheobronchial colonization was defined as positive respiratory specimen culture. VAP was defined by the presence of new or progressive radiographic infiltrate associated with two of the following criteria: temperature \> 38.5 °C or \< 36.5 °C, leukocyte count \> 10,000/μl or \< 1,500/μl, purulent tracheal aspirate; and positive (≥ 10^6^ cfu/ml) endotracheal aspirate. Only VAP episodes occurring more than 48 h after the commencement of mechanical ventilation were taken into account.

Matching criteria {#Sec4}
-----------------

Cases were patients with *P. aeruginosa* VAP or tracheobronchial colonization; controls, patients without *P. aeruginosa* VAP or tracheobronchial colonization. Every case was matched with two controls according to all the following criteria: (1) duration of mechanical ventilation before first positive respiratory specimen for *P. aeruginosa* (controls ≥ cases), (2) admission category (medical/surgical), (3) immunologic status, and (4) date of ICU admission when more than two potential control patients were available.

Statistical analysis {#Sec5}
--------------------

Qualitative variables were compared using the χ^2^ test or Fisher\'s exact test where appropriate. The Mann--Whitney U-test was used to compare quantitative variables.

To determine variables associated with *P. aeruginosa* VAP or tracheobronchial colonization, cases were compared with controls by univariate and multivariate analyses.

Please see the electronic supplementary material (ESM) for additional information.

Results {#Sec6}
=======

One hundred and seventeen patients were eligible. Fifteen patients were excluded because *P. aeruginosa* VAP or tracheobronchial colonization was diagnosed before or at the same time as *Candida* spp. tracheobronchial colonization.

Mycology results and antifungal treatment {#Sec7}
-----------------------------------------

130 *Candida* spp. were isolated in the 102 study patients. *C. albicans* was the most frequently isolated species (67%). Thirty-six patients (35%) received antifungal treatment. The mean duration of antifungal treatment was 13 ± 12 days. Fluconazole was the most frequently used antifungal (66%). Indications for antifungal treatment included: candidemia (*n* = 3), pneumonia in immunosuppressed patients (*n* = 8), peritonitis (*n* = 6), and preemptive therapy (*n* = 19).

Characteristics of study patients {#Sec8}
---------------------------------

The characteristics of the study patients are presented in Table [1](#Tab1){ref-type="table"}. The durations of ICU stay and of antifungal treatment were highly colinear (*r* = 0.716). Table 1Patient characteristicsAntifungal treatment (*n* = 36)No antifungal treatment (*n* = 66)*p*Age, years60 ± 1758 ± 160.286Male gender13 (36)29 (43)0.290SAPS II48 ± 1649 ± 180.796LOD score5 ± 36 ± 40.792Surgery9 (25)10 (15)0.169Diabetes mellitus10 (27)13 (19)0.245Prior antibiotic treatment19 (52)20 (30)0.029\*Immunosuppression8 (22)2 (3)0.003\*Chronic respiratory disease15 (41)29 (43)0.496Chronic heart failure8 (22)12 (18)0.403Cirrhosis4 (11)2 (3)0.114Chronic renal failure1 (2)7 (10)0.154Cause for ICU admission ARDS5 (13)2 (3)0.051 Pneumonia11 (30)16 (24)0.321   CAP4 (11)13 (19)0.204   HAP7 (19)3 (4)0.021\* Acute exacerbation of COPD8 (22)16 (24)0.511 Acute poisoning3 (8)4 (6)0.476 Septic shock4 (11)11 (16)0.328Congestive heart failure2 (5)1 (1)0.716Cellulitis1 (2)5 (3)0.306Others2 (5)11 (16)0.093During ICU stayDays of MV free of *P. aeruginosa*21 ± 1513 ± 90.003Number of *Candida*-colonized sites1.7 ± 11.4 ± 0.60.099Duration of MV before *Candida* colonization4 ± 64 ± 60.574 Antibiotic treatment17 (89)35 (92)0.545   Antipseudomonal antibiotics14 (38)26 (39)0.566   Non-antipseudomonal 3GC10 (27)20 (30)0.488   Other antibiotics33 (91)55 (83)0.195 Duration of antibiotic treatment, days24 ± 1412 ± 8\< 0.001 Duration of MV, days30 ± 2216 ± 14\< 0.001 Duration of ICU-stay, days35 ± 2618 ± 17\< 0.001 ICU mortality19 (48)21 (31)0.032\*Data are expressed as number (%) or mean ± SD. *SAPS*Simplified Acute Physiology Score, *LOD*logistic organ dysfunction, *ARDS*acute respiratory distress syndrome, *CAP*community-acquired pneumonia, *HAP* hospital-acquired pneumonia, *MV* mechanical ventilation,*3GC*third-generation cephalosporins. \*OR (95% CI) = 2.4 (1--5.7), 3.4 (1--12), 5 (1.2--21), 2.3 (1--5.5), respectively, from top to bottom

Risk factors for *P. aeruginosa* VAP or tracheobronchial colonization {#Sec9}
---------------------------------------------------------------------

Nineteen patients developed a *P. aeruginosa* VAP or tracheobronchial colonization, including 13 patients who received antifungal treatment (7 patients before antifungal treatment, 4 patients during antifungal treatment, and 2 patients after antifungal treatment), and 6 patients who did not receive antifungal treatment. Among the 19 patients with *P. aeruginosa* VAP or tracheobronchial colonization, 10 developed at least one VAP episode, and 9 remained colonized.

The 19 patients with *P. aeruginosa* VAP or tracheobronchial colonization were all successfully matched with 2 control patients each for a total of 38 controls. Results of univariate analysis are presented in Table [2](#Tab2){ref-type="table"}. Multivariate analysis identified antifungal treatment as the only factor independently associated with *P. aeruginosa* VAP or tracheobronchial colonization (OR = 0.68, 95% CI = 0.49--0.90, *p* = 0.046). Table 2Risk factors for ventilator-associated pneumonia or tracheobronchial colonization related to *Pseudomonas aeruginosa* in univariate analysisCases (*n* = 19)Controls (*n* = 38)*p*At ICU admissionAge, years63 ± 1359 ± 160.402Male gender10 (52)24 (63)0.315SAPS II49 ± 2149 ± 170.803LOD score6 ± 46 ± 30.966Surgery3 (15)6 (15)0.639Diabetes mellitus6 (31)10 (26)0.452Prior antibiotic treatment7 (36)20 (52)0.174Immunosuppression2 (10)4 (10)0.661Chronic respiratory disease8 (42)22 (57)0.199Chronic heart failure4 (21)10 (26)0.464Cirrhosis2 (10)3 (7)0.545Chronic renal failure2 (10)2 (5)0.407Cause for ICU admissionARDS1 (5)2 (5)0.712Pneumonia6 (31)13 (34)0.544CAP1 (5)10 (25)0.055HAP5 (26)3 (7)0.072Acute exacerbation of COPD5 (26)11 (26)0.548Acute poisoning2 (10)1 (2)0.255Septic shock2 (10)5 (13)0.571Congestive heart failure1 (5)1 (2)0.560Others2 (10)5 (13)0.661During ICU stayNumber of *Candida*-colonized sites1.2 ± 0.61.9 ± 1.30.121Antifungal treatment6 (31)23 (60)0.037\*Duration of antifungal treatment, days7 ± 1114 ± 140.045Antibiotic treatment17 (89)35 (92)0.545Antipseudomonal antibiotics6 (31)17 (44)0.254Non-antipseudomonal 3GC8 (42)9 (23)0.131Other antibiotics17 (89)33 (86)0.571Duration of antibiotic treatment, days13 ± 618 ± 140.536Duration of mechanical ventilation, days16 ± 722 ± 150.333Data are expressed as number (%) or mean ± SD. In cases, only exposure to potential risk factors before first positive respiratory specimen for *P. aeruginosa* was taken into account. *SAPS*simplified acute physiology score, *LOD*logistic organ dysfunction, *ARDS*acute respiratory distress syndrome, *CAP*community-acquired pneumonia, *HAP* hospital-acquired pneumonia, *3GC*third generation cephalosporins. \*OR (95% CI) = 0.67 (0.45--0.90)

Please see the ESM for additional results.

Discussion {#Sec10}
==========

Our results suggest that antifungal treatment is associated with reduced risk for VAP or tracheobronchial colonization related to *P. aeruginosa*. To our knowledge, this study is the first to evaluate the impact of antifungal treatment on *Candida* spp. and *P. aeruginosa* interaction. Several studies have identified pathogenic interactions between microorganisms, such as herpes simplex virus and human immunodeficiency virus; influenza virus and *P. aeruginosa*; and *C. albicans* and *P. aeruginosa* \[[@CR5], [@CR9], [@CR10]\]. Theses interactions have major environmental and medical consequences. A pathogenic interaction between *C. albicans* and *P. aeruginosa* has been demonstrated in experimental studies. Recent *P. aeruginosa* infection has been identified as a risk factor for fatal candidiasis in burned mice \[[@CR11]\]. Molecular studies identified phylogenetic similarities between the two pathogens \[[@CR5], [@CR6]\]. The morphology and virulence of *C. albicans* are significantly affected by the presence of *P. aeruginosa* \[[@CR5]\]. A cell--cell signaling molecule capable of inhibiting *C. albicans* filamentation is produced by *P. aeruginosa* \[[@CR5]\]. *P. aeruginosa* forms a dense biofilm on *C. albicans* filaments and kills the fungus. In contrast, *P. aeruginosa* neither binds nor kills yeast-form *C. albicans*. Several *P. aeruginosa* virulence factors that are important in disease are involved in killing of *C. albicans* filaments \[[@CR5]\]. Azoulay et al. \[[@CR8]\] recently reported the results of the first clinical study suggesting an interaction between *C. albicans* and *P. aeruginosa*. The authors identified *Candida* spp. tracheobronchial colonization as an independent risk factor for *P. aeruginosa* pneumonia. No cause-and-effect relationship was demonstrated in that study. In addition, *Candida* spp. tracheobronchial colonization and *P. aeruginosa* pneumonia could both be a consequence of prior antibiotic treatment. However, the lack of association with *Staphylococcus aureus* pneumonia, another consequence of antibiotic treatment, indicates that an association between *Candida* spp. tracheobronchial colonization and *P. aeruginosa* remains plausible. A more recent experimental study has evaluated the impact of *C. albicans* tracheobronchial colonization on the occurrence of *P. aeruginosa* pneumonia \[[@CR12]\]. Rate of *P. aeruginosa* pneumonia was significantly higher in rats with *C. albicans* tracheobronchial colonization as compared with rats without *C. albicans* tracheobronchial colonization (33% vs 4%, *p* \< 0.05).

Although antifungal treatment was associated with reduced risk for *P. aeruginosa* VAP or tracheobronchial colonization, no significant relationship was found between antifungal treatment and *P. aeruginosa* VAP. However, the small number of patients with VAP precludes a definite conclusion. In addition, a recent meta-analysis outlined the similarity of risk factors for colonization and infection related to multidrug-resistant bacteria \[[@CR4]\]. Moreover, our results may provide support for the notion that the interaction between *Candida* spp. and *P. aeruginosa* is at bronchial or biofilm level.

Bacterial biofilm has been demonstrated on inner surface of endotracheal tubes removed from mechanically ventilated patients. Bacterial biofilm may play an important role as a persistent source of infectious material for recurrent episodes of VAP \[[@CR13]\]. *Candida* spp. and *P. aeruginosa* are the most common pathogens retrieved from endotracheal tube biofilm and tracheal secretions in patients with VAP \[[@CR14]\]. Although all *Candida* spp. were taken into account in our study, previous experimental studies \[[@CR5], [@CR6], [@CR12]\] were performed exclusively on *C. albicans.* However, in the study by Azoulay et al. \[[@CR8]\] tracheobronchial colonization with any *Candida* spp. was identified as a risk factor for *P. aeruginosa* VAP. Further studies are needed to determine whether *Candida* spp. and *P. aeruginosa* interaction could be influenced by the nature of *Candida* spp.

Inclusion of immunosuppressed patients could be a matter of debate. However, immunologic status was a matching criterion. Future randomized interventional studies on the impact of antifungal treatment on *P. aeruginosa* VAP or tracheobronchial colonization should be conducted in immunocompetent patients.

Our study has several limitations. First, this was a retrospective observational study. Second, some of the trends observed in this study could have reached statistical significance if more patients had been included. In addition, the number of patients needed to demonstrate a beneficial effect of antifungal treatment was not calculated a priori. Third, our study was conducted in a single ICU. Therefore, our results may not be generalizable to other ICUs. Fourth, no information was available on the nature of prior antibiotic treatment or and on the quantity of *Candida* spp. in respiratory specimens. In addition, invasive methods were not used to diagnose VAP. However, quantitative tracheal aspirate culture was used in all patients with a high threshold (≥ 10^6^ cfu/ml). Postmortem studies showed acceptable overall diagnostic accuracy of quantitative tracheal aspirate compared with bronchoalveolar lavage or protected specimen brush \[[@CR15]\]. Finally, antifungal treatment was based on medical staff decisions. Among the 36 patients who received antifungals, 19 patients received preemptive antifungal treatment. This finding is consistent with the results of a recent survey conducted in French ICUs \[[@CR16]\]. However, recovery of *Candida* spp. from the respiratory tract of mechanically ventilated patients without risk factors for immunosuppression is common and frequently reflects a tracheobronchial colonization \[[@CR17], [@CR18]\]. Some authors suggest that antifungal treatment should be based on the colonization index in these patients \[[@CR19], [@CR20]\].

We conclude that in patients with *Candida* spp. tracheobronchial colonization, antifungal treatment is associated with reduced risk for *P. aeruginosa* VAP or tracheobronchial colonization. Prospective randomized studies are required to confirm this result.
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